Tiziana Life Sciences Ltd
corporate_fare Company Profile
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for TLSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for TLSA spans 6-K, 4.
Recent high-impact activity:
- Tiziana Sets Nov 9 KOL Call, Quantifies INFORM-MS Wins (p=0.0168)
- Tiziana's INFORM-MS Phase 2a Hits Both Primary Endpoints in na-SPMS
- Phase 2a Win: Intranasal Foralumab Cuts Neuroinflammation in Progressive MS
- Tiziana H1 Loss Widens to $12.4M; Going-Concern Doubt With $3.9M Cash
- Tiziana Doses Last Alzheimer's Patient; Phase 2 Topline Data Due Q1 2027
Financial Snapshot
Short Interest & Short Volume
6.98 days to coverFINRA reported short interest of 2,922,342 shares in TLSA as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 44.5% of TLSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
TLSA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.